(Total Views: 439)
Posted On: 03/27/2021 10:03:25 AM
Post# of 148924
This is an excellent post, and right on the money in my opinion.
In the last CC, Dr Kelly said that this company would most likely become "an oncology company". Very exciting given the massive opportunity there. And HIV - we've already hit a home run in our trial. And that's not a throwaway market either.
So why are we mired in the long (and extremely costly) swamp of chasing COVID? I know we've got a lot of sunk cost in it already, but it seems to be hell bent and determined to thwart our efforts as it's a brand new, foreign and very complicated disease. No matter what they say, we have taken our eye off the other balls while chasing trial after trial. and if the next trial misses the PE, i am going to be very concerned - and my gut is that we see another raise at a very low SP.
I say it's time to treat COVID as "gravy on top of our core business" and partner up and let some big company with a team of scientists run with it. Hell, even if we got 25% of what we originally thought we'd get in that space, it would be a windfall that would propel our stock price and accelerate the real goal of the company.
i really hope there's something i'm missing - and they know a lot that we don't. and importantly, that COVID doesn't become the slow motion train wreck that i worried about a long time ago when we started down that path. Not saying i knew it would be a mistake, but i wondered why we didn't just hammer home the fat pitches that were in front of us.....
In the last CC, Dr Kelly said that this company would most likely become "an oncology company". Very exciting given the massive opportunity there. And HIV - we've already hit a home run in our trial. And that's not a throwaway market either.
So why are we mired in the long (and extremely costly) swamp of chasing COVID? I know we've got a lot of sunk cost in it already, but it seems to be hell bent and determined to thwart our efforts as it's a brand new, foreign and very complicated disease. No matter what they say, we have taken our eye off the other balls while chasing trial after trial. and if the next trial misses the PE, i am going to be very concerned - and my gut is that we see another raise at a very low SP.
I say it's time to treat COVID as "gravy on top of our core business" and partner up and let some big company with a team of scientists run with it. Hell, even if we got 25% of what we originally thought we'd get in that space, it would be a windfall that would propel our stock price and accelerate the real goal of the company.
i really hope there's something i'm missing - and they know a lot that we don't. and importantly, that COVID doesn't become the slow motion train wreck that i worried about a long time ago when we started down that path. Not saying i knew it would be a mistake, but i wondered why we didn't just hammer home the fat pitches that were in front of us.....
(3)
(0)Scroll down for more posts ▼
